All In Biotech

Drug Trial Radar · NCT06088199

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

51

Actual

Start

Oct 24, 2023

Primary completion

Aug 12, 2026

Study completion Aug 12, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • ApremilastDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse EventsTime frame: Day 1 up to approximately 285 days

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Affiliated Dermatology

    Scottsdale, Arizona

  • Clear Dermatology

    Scottsdale, Arizona

  • Johnson Dermatology Clinic

    Fort Smith, Arkansas

  • Avance Clinical Trials

    Laguna Niguel, California

  • University of California Irvine

    Orange, California

  • MedDerm Associates

    San Diego, California

  • Clinical Science Institute

    Santa Monica, California

  • California Dermatology Institute

    Thousand Oaks, California

  • Pediatric Skin Research LLC

    Coral Gables, Florida

  • Ciocca Dermatology

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Endeavor Health Clinical Trials Center

    Skokie, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Southern Indiana Clinical Trials

    New Albany, Indiana

  • Great Lakes Research Group Inc- Sheffield

    Bay City, Michigan

  • Henry Ford Medical Center - New Center One

    Detroit, Michigan

  • Dermatology and Skin Cancer Center of Lees Summit

    Lee's Summit, Missouri

  • Boeson Research

    Missoula, Montana

  • Empire Dermatology

    East Syracuse, New York

  • State University of New York, Downstate Medical Center

    Manhasset, New York

  • OptiSkin Medical

    New York, New York

  • Hightower Clinical LLC

    Oklahoma City, Oklahoma

  • Dermatology Research Center of Oklahoma, PLLC

    Tulsa, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • Medical University of South Carolina

    Charleston, South Carolina

  • Studies in Dermatology LLC

    Cypress, Texas

  • Austin Institute for Clinical Research

    Pflugerville, Texas

  • Stride Clinical Research LLC

    Sugar Land, Texas

  • Frontier Derm Partners

    Mill Creek, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.